The AADA has cautioned that these reductions may affect access to essential dermatologic services, including timely skin cancer diagnosis and treatment.
▶ Why it matters: Reimbursement changes can influence scheduling, staffing, procedure availability, and practice sustainability. Dermatology teams should evaluate how the 2027 policies may affect their service mix, documentation practices, and financial planning while monitoring additional AADA guidance.
Chronic Hand Eczema Findings Highlight Opportunities for Earlier Recognition
New research highlighted in the November 16 Journal Digest found that 9.6% of 10,636 surveyed US adults reported a health care professional diagnosis of chronic hand eczema. Prevalence exceeded 13% among adults aged 18 to 39 years and was higher among employed and urban populations.
The findings underscore the burden of persistent and recurrent hand dermatitis, particularly among working-age adults who may experience repeated exposure to occupational irritants and allergens.
For dermatology clinicians, distinguishing chronic hand eczema from transient irritation and identifying relevant exposures remain important components of assessment and management.
▶ Why it matters: Chronic hand eczema can interfere with employment, daily activities, and quality of life. NPs and PAs can help identify patients who may benefit from additional evaluation, individualized skin protection strategies, and treatment escalation when conventional approaches are insufficient.
Get Involved With Dermatology Times
For APPs across all stages of their dermatology careers, opportunities to connect, learn, and share experiences can be an important part of professional growth. Dermatology Times invites nurse practitioners and physician assistants to share their perspectives through NP/PA Connect. APPs can contribute clinical insights, career experiences, advocacy efforts, lessons learned, and perspectives on emerging treatments while connecting with colleagues across the dermatology community.
Interested in getting involved? Contact editor Shannon Heaning at sheaning@mjhlifesciences.com to contribute.
Biologic Response Patterns May Help Guide HS Treatment Optimization
A recent cohort study involving 107 patients with hidradenitis suppurativa (HS) explored whether symptom recurrence near the end of a biologic dosing interval could inform treatment adjustments.
Patients experiencing an end-of-dose effect underwent biologic dose intensification, whereas those without this pattern received adjunctive long-term antibiotics. The response-guided approach was associated with improvements across 7 clinical outcomes within 3 to 5 months, with benefits sustained through subsequent follow-up.
Although the nonrandomized design limits conclusions about comparative effectiveness, the findings suggest that the timing of symptom recurrence may provide useful information when evaluating incomplete treatment responses.
▶ Why it matters: When patients report persistent HS symptoms despite biologic therapy, understanding when flares occur may help clinicians distinguish possible waning treatment effects from ongoing inflammatory activity. Documenting symptom patterns can support more individualized treatment discussions, while recognizing that dosing changes require consideration of evidence, labeling, safety, and coverage.
Melanoma Risk Models Reinforce the Need for Clinical Judgment
As dermatology practices increasingly explore risk prediction tools, new findings highlight the importance of evaluating their performance before incorporating them into routine care.
A study assessing 6 melanoma risk prediction models found variable discriminatory performance, with areas under the receiver operating characteristic curve ranging from 0.58 to 0.70. Most models underestimated melanoma risk in the population studied.
The results emphasize that prediction tools may not perform consistently across patient populations and that external validation and recalibration are important before clinical implementation.
▶ Why it matters: Risk prediction tools may eventually help dermatology teams prioritize screening, counseling, and surveillance. However, clinicians should avoid relying on model-generated estimates in isolation. Patient history, clinical examination, established risk factors, and individualized judgment remain essential to melanoma prevention and early detection.
References
- Heaning S. FDA implements updated iPLEDGE REMS requirements for isotretinoin. Dermatology Times. Published November 16, 2026.
- Heaning S. AADA warns of 6% Medicare payment cut for dermatologists in 2027. Dermatology Times. Published November 5, 2026.
- Heaning S. Journal Digest: November 16. Dermatology Times. Published November 16, 2026.
Dermatology Times NP/PA Connect | The Practice Brief